Examining the Immunological Process of Autoimmune Patients
NCT02123147 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2017-08-08
Summary
Sjögren's syndrome (SjS) is an autoimmune disease characterized primarily by exocrine gland dysfunction, specifically of the salivary and lacrimal glands, resulting in dry mouth and dry eyes symptoms. It can be systemic by affecting other organs including the gastrointestinal tract, skin, lungs, vasculature, kidneys, bladder and vagina. Involvement of the musculature can lead to fibromyalgia-like symptoms and chronic fatigue, while approximately 20% of patients develop various neuropathies, including sensory, peripheral, cranial and myelopathic neuropathies exhibited by cognitive impairments such as dementia, lack of concentration, memory loss and various psychiatric disorders. Like most autoimmune connective tissue diseases, SjS shows a sexual dimorphism with women affected 10-times more frequently than men, suggesting a role for sex hormones in disease susceptibility or progression. One common feature of SjS is it infiltration of mononuclear cells into the salivary and lacrimal glands, aggregating into clusters referred to as lymphocytic foci (LF). Critical to the studies proposed is the fact that a predominant cell population of LF is the pathogenic TH17 cell that produces IL-17 cytokine and autoreactive B cells reactive to M3R, Ro, and La autoantigens. The goal of this study is characterize the change in receptor gene repertoires of autoreactive B and T cells at different time points during the disease process and examine the correlation with various disease parameters.
Conditions
- Sjogren's Syndrome
- Autoimmune Diseases
- Dry Eyes
- Dry Mouth
Sponsors & Collaborators
-
University of Florida
lead OTHER
Principal Investigators
-
Cuong Nguyen, PhD · University of Florida
Eligibility
- Min Age
- 9 Years
- Max Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-07-31
- Primary Completion
- 2016-08-31
- Completion
- 2016-08-31
Countries
- United States
Study Locations
More Related Trials
-
Efficacy of Tocilizumab in Primary Sjögren's Syndrome.
NCT01782235 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Oral Manifestations of Systemic Sclerosis
NCT02371005 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease
NCT05177471 ·Status: WITHDRAWN
-
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NCT04837131 ·Status: TERMINATED ·Phase: PHASE2
-
N-acetylcysteine for Primary Sjögren's Syndrome
NCT04793646 ·Status: COMPLETED ·Phase: NA
-
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
NCT00883129 ·Status: COMPLETED ·Phase: PHASE2
-
AUTOANTIBODIES AND SYSTEMIC SCLEROSIS
NCT06502678 ·Status: NOT_YET_RECRUITING
-
Oral Type I Collagen for Relieving Scleroderma
NCT00005675 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF
NCT06758947 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
NCT01553981 ·Status: COMPLETED ·Phase: PHASE3
-
Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
NCT03509064 ·Status: RECRUITING
-
Prevalence and Factors of Sarcopenia and in Patients With Primary Sjogren's Syndrome
NCT05015114 ·Status: COMPLETED
-
Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis
NCT02105818 ·Status: COMPLETED
-
Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.
NCT05171114 ·Status: COMPLETED ·Phase: NA
-
Prevalence of Hyperprolactinemia in Systemic Scleroderma
NCT04746313 ·Status: COMPLETED
-
Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers
NCT01971957 ·Status: COMPLETED
-
NVC Test in Order to Assess Pathological Changes in Family Members of Patient Diagnosed With SSc
NCT02795221 ·Status: UNKNOWN
-
Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
NCT05380804 ·Status: COMPLETED
-
Penn SICCA Follow-up Study
NCT05056012 ·Status: NOT_YET_RECRUITING
-
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
NCT02887495 ·Status: COMPLETED
-
Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
NCT06568783 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Analysis of Cytokine Expression Pattern in Systemic Sclerosis
NCT03537105 ·Status: COMPLETED ·Phase: NA
-
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
NCT04986514 ·Status: WITHDRAWN
-
What is the Optimal Follow-up for Patients With Systemic Sclerosis?
NCT05103553 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Exercise With Scleroderma Functional Outcomes
NCT06425653 ·Status: COMPLETED ·Phase: NA